최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기성인간호학회지 = Korean Journal of Adult Nursing, v.28 no.3, 2016년, pp.314 - 322
조관숙 (가톨릭대학교 서울성모병원 간호부) , 반자영 (가톨릭대학교 서울성모병원 간호부) , 윤지연 (가톨릭대학교 서울성모병원 간호부) , 국승혜 (가톨릭대학교 서울성모병원 간호부) , 윤현선 (가톨릭대학교 서울성모병원 간호부) , 유양숙 (가톨릭대학교 간호대학)
Purpose: The purpose of this study was to identify the quality of life reported by patients with multiple myeloma and secondly to identify the factors that impact the quality of life (QoL). Methods: 189 patients with multiple myeloma completed survey questionnaires. Quality of life was evaluated usi...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
다발성 골수종은 어떠한 특성이 있는가? | 다발성 골수종은 두 번째로 많이 발생하고 있는 혈액암으로[1], B 세포에서 유래되는 형질세포가 비정상적으로 증식하여 M 단백을 과잉생산하는 특성이 있다[2,3]. 다발성 골수종은 노인에게 호발하는데[4], 최근 평균 수명의 연장과 인구 고령화로 더욱 증가할 것으로 전망되고 있어[5], 치료 성적과 삶의 질에 대한 관심이 커지고 있다. | |
다발성 골수종은 어떤 연령대에서 호발하는가? | 다발성 골수종은 두 번째로 많이 발생하고 있는 혈액암으로[1], B 세포에서 유래되는 형질세포가 비정상적으로 증식하여 M 단백을 과잉생산하는 특성이 있다[2,3]. 다발성 골수종은 노인에게 호발하는데[4], 최근 평균 수명의 연장과 인구 고령화로 더욱 증가할 것으로 전망되고 있어[5], 치료 성적과 삶의 질에 대한 관심이 커지고 있다. | |
다발성 골수종 환자들에게 탈리도마이드나 보르테조밉을 사용하였을 시 유발될 수 있는 부작용은? | 다발성 골수종 환자들은 치료과정에서 불면이나 변비, 부종, 어지러움, 두통, 오심과 구토, 시야 흐림 등의 부작용을 경험할 수 있다[7]. 특히 자가 조혈모세포이식을 위한 관해유도제로 사용하는 탈리도마이드나 자가 조혈모세포이식을 할 수 없는 환자에게 많이 사용하는 보르테조밉[1,5]은 말초 신경병증을 유발하여 일부 환자들은 통증이나 마비로 일상생활이 불가능해지기도 하며, 치료를 중단하기도 한다[6]. 그러므로 다발성 골수종 환자들이 치료 과정에서 경험하는 부작용과 이로 인한 삶의 질을 파악하여 고통을 완화하고 삶의 질을 향상시키려는 노력이 필요하다. |
Kumar S. Treatment of newly diagnosed multiple myeloma: advances in current therapy. Medical Oncology. 2010;27(Suppl 1):S14-24. http://dx.doi.org/10.1007/s12032-009-9370-1
Bilotti E, Faiman BM, Richards TA, Tariman JD, Miceli TS, Rome SI. Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the international myeloma foundation nurse leadership board. Clinical Journal of Oncology Nursing. 2011;15(4):5-8. http://dx.doi.org/10.1188/11.s1.cjon.5-8
Smith D, Yong K. Multiple myeloma. British Medical Journal. 2013;346:3863. http://dx.doi.org/10.1136/bmj.f3863
Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European Journal of Cancer. 2007;43(11):1670-8. http://dx.doi.org/10.1016/j.ejca.2007.04.022
Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clinical Cancer Research. 2011;17(6):1253-63. http://dx.doi.org/10.1158/1078-0432.ccr-10-1925
Comert M, Gunes AE, Sahin F, Saydam G. Quality of life and supportive care in multiple myeloma. Turkish Journal of Haematology. 2013;30(3):234-46. http://dx.doi.org/10.4274/Tjh.2012.0192
Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European multicenter cohort study. Supportive Care in Cancer. 2014;22(2):417-26. http://dx.doi.org/10.1007/s00520-013-1991-4
Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. European Journal of Haematology. 2012;89(6):437-57. http://dx.doi.org/10.1111/ejh.12012
Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation. 2009;15(1):12-20. http://dx.doi.org/10.1016/j.bbmt.2008.09.023
Khalafallah A, McDonnell K, Dawar HU, Robertson I, Woods D. Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation. Mediterranean Journal of Hematology and Infectious Disease. 2011;3(1):e2011057. http://dx.doi.org/10.4084/mjhid.2011.057
Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27(10):1959-69. http://dx.doi.org/10.1038/leu.2013.185
Corso A, Mangiacavalli S, Cocito F, Pascutto C, Ferretti VV, Pompa A, et al. Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis. The Public Library of Science One. 2013;8(9):e75047. http://dx.doi.org/10.1371/journal.pone.0075047
Stead ML, Brown JM, Velikova G, Kaasa S, Wisloff F, Child JA, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. British Journal of Haematology. 1999;104(3):605-11.
Kontodimopoulos N, Samartzis A, Papadopoulos AA, Niakas D. Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma. The Scientific World Journal. 2012;2012:842-67. http://dx.doi.org/10.1100/2012/842867
Kim HS, Yi MS. Factors influencing quality of life in multiple myeloma. Asian Oncology Nursing. 2015;15(1):9-17.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology. 1982;5(6):649-55.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14.
Kim JH, Choi KS, Kim T, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. Asian Oncology Nursing. 2011;11(3):254-62.
Yang JY, Lee MS. Factors influencing quality of life in thyroid cancer patients with thyroidectomy. Asian Oncology Nursing. 2015;15(2):59-66.
Can G, Demir M, Erol O, Aydiner A. A comparison of men and women's experiences of chemotherapy-induced alopecia. European Journal of Oncology Nursing. 2013;17(3):255-60. http://dx.doi.org/10.1016/j.ejon.2012.06.003
Goodwin JA, Coleman EA, Sullivan E, Easley R, McNatt PK, Chowdhury N, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nursing. 2013;36(4):301-8. http://dx.doi.org/10.1097/NCC.0b013e3182693522
Kirchhoff AC, Leisenring W, Syrjala KL. Prospective predictors of return to work in the 5 years after hematopoietic stem cell transplantation. Journal of Cancer Survivorship: Research and Practice. 2010;4(1):33-44. http://dx.doi.org/10.1007/s11764-009-0105-2
Song BE, Kang HR, Kim KS. Quality of life in patients with hematopoietic stem cell transplantation. Asian Oncology Nursing. 2008;8(1):40-9.
Faiman B. Clinical updates and nursing considerations for patients with multiple myeloma. Clinical Journal of Oncology Nursing. 2007;11(6):831-40. http://dx.doi.org/10.1188/07.cjon.831-840
Kurtin S, Faiman B. The changing landscape of multiple myeloma: implications for oncology nurses. Clinical Journal of Oncology Nursing. 2013;17(Suppl):7-11. http://dx.doi.org/10.1188/13.cjon.s2.7-11
※ AI-Helper는 부적절한 답변을 할 수 있습니다.